Chemomab Therapeutics's quarterly market cap
declined
from Jun. 2023 ($15.54 Mil) to Dec. 2023 ($7.24 Mil) but then
increased
from Dec. 2023 ($7.24 Mil) to Mar. 2024 ($11.08 Mil).
Chemomab Therapeutics's annual market cap
declined
from Dec. 2021 ($78.69 Mil) to Dec. 2022 ($35.36 Mil) and
declined
from Dec. 2022 ($35.36 Mil) to Dec. 2023 ($7.24 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chemomab Therapeutics's Enterprise Value for Today is $-1.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Chemomab Therapeutics's Market Cap
For the Biotechnology subindustry, Chemomab Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemomab Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chemomab Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Chemomab Therapeutics's Market Cap falls into.
Chemomab Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Chemomab Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics (NAS:CMMB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Chemomab Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Chemomab Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Chemomab Therapeutics (Chemomab Therapeutics) Business Description
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet need. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CMMB has been successfully added to your 